Trial of Dasatinib in Advanced Sarcomas

This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.

Principal Investigator

CONTACT INFORMATION

Primary Contact:
Maria Ahern
(650) 725-6413